ホームMCPワークベンチSkills
ホームワークベンチ通知マイページ
化工社オープンプロジェクト:[email protected]AIアクセス:llms.txt · MCPガイドプライバシーポリシー · 利用規約 · サポートv1.7.8
  1. ホーム
  2. /化合物

フェナセチン

Phenacetin

HCID 4754
ノート反応
基本情報概要名称と識別子物性安全と法規制化学と産業関連反応化合物ノート
部分構造検索類似構造を探す

基本情報

CAS
40674-52-0
標準SMILES
CCOc1ccc(NC(C)=O)cc1
InChIKey
CPJSUEIXXCENMM-UHFFFAOYSA-N
分子式
C10H13NO2
平均分子量
179.22 g/mol
単同位体質量
179.09462866

概要

Phenacetin can cause cancer according to California Labor Code.

名称と識別子

優先名称
Phenacetin
IUPAC
N-(4-ethoxyphenyl)acetamide
現地名
フェナセチン
英語名
Phenacetin
分子式
C10H13NO2
分子量
179.22

名称と別名

phenacetin62-44-2N-(4-Ethoxyphenyl)acetamideAcetophenetidinAcetophenetidineAcetophenetinAcetphenetidinPhenacetinePhenazetinp-AcetophenetididePhenacetinumFenidina
名称をさらに表示
フェナセチンフェナゼチナp-アセトフェネチジドフェナゼチンフェニジンp-アセトフェネチド4'-エトキシアセトアニリドアセトフェネチンアセト-p-フェナリドフェネジナN-(4-エトキシフェニル)アセトアミドN-アセチル-p-フェネチジンマレックスフェナセチヌムアセト-p-フェネチジドN-アセチル-4-エトキシアニリンN-(p-エトキシフェニル)アセトアミドp-アセトフェネチジンアセトフェネチジンペルトナールFenacetinPhenacitinSomaP-ETHOXYACETANILIDE4-ETHOXYACETANILIDEWigraineSinutabNorgesic
KalminAchrocidinCodempiralContradolContradouleurFenacetinaPhenedinap-Acetophenetidine

物性

構造計算による物性

XLogP
1.6
極性表面積
38.3 Ų
水素結合供与体数
1
水素結合受容体数
2
回転可能結合数
3
重原子数
13
形式電荷
0
複雑度
162

実験および物理化学的性質

Chemical ClassesCarcinogens
Drugs · 2 件

DEA NFLIS-Drug Category -> Analgesics

Pharmaceuticals -> Listed in ZINC15

Cosmetics · 2 件

Stabilizing

Personal care product

pHSATURATED SOLN IS NEUTRAL TO LITMUS
SpringerMaterials PropertiesBoiling point
LogP · 2 件

log Kow = 1.58

1.65

OdorODORLESS
TasteSlightly bitter
Color/Form · 4 件

Monoclinic prisms

Crystalline scales or powder

Solid

WHITE, GLISTENING CRYSTALS, USUALLY SCALES, OR AS FINE WHITE, CRYSTALLINE POWDER

Solubility · 5 件

less than 1 mg/mL at 68 °F (NTP, 1992)

1 g dissolves in 1310 mL cold water, 82 mL boiling water, 15 mL cold alcohol, 2.8 mL boiling alcohol, 14 mL chloroform, 90 mL ether; sol in glycerol.

Very sol in pyrimidine; sol in ethanol, acetone; slightly sol in benzene. ethyl ether.

安全と法規制

安全情報は参考情報です。供給元の安全データシート(SDS)、適用法令、専門家による評価に代わるものではありません。

GHS分類

GHS Classification · 6 件

Danger

H302 (100%): Harmful if swallowed [Warning Acute toxicity, oral]

P203, P264, P270, P280, P301+P317, P318, P330, P405, and P501 (click each P-code to see the statement)

Aggregated GHS information provided per 111 reports by companies from 9 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.

Danger

H302 (100%): Harmful if swallowed [Warning Acute toxicity, oral]

危険有害性情報

Regulatory Information · 6 件

Chemical: Acetamide, N-(4-ethoxyphenyl)-

Hazard Traits - Carcinogenicity

Acetamide, N-(4-ethoxyphenyl)- is listed on the EPA's Chemical Data Reporting (CDR) system. Manufacturers and importers of Acetamide, N-(4-ethoxyphenyl)- are required to report information about their production and use of this chemical to the EPA under the Toxic Substances Control Act (TSCA). (40 eCFR Part 711)

S - indicates a substance that is identified in a final Significant New Use Rule.

Status: Active Update: 09-03-2023 https://echa.europa.eu/registration-dossier/-/registered-dossier/34595

Acetamide, N-(4-ethoxyphenyl)-: Does not have an individual approval but may be used under an appropriate group standard

Other Safety InformationIMAP assessments - CMR chemicals not registered under REACH: Human health tier II assessment
Fire HazardsFlash point data for this compound are not available but it is probably combustible. (NTP, 1992)
Health Hazards · 1 件

SYMPTOMS: Symptoms following exposure to this compound may include weakness, dizziness, depression, collapse, cyanosis, sweating, gastric irritation, chills, fall in blood pressure, jaundice, coma, convulsions, weight loss, insomnia, shortness of breath, aplastic anemia, and damage to the liver, kidneys, heart and central nervous system.

化学と産業

薬理情報

ATC Code · 2 件

N - Nervous system

QN - Nervous system

Pharmacodynamics · 1 件

Phenacetin was the first NSAID and fever reducer to go on the market. It acts as an analgesic at the spinal cord as well as a negative inotrope at the heart. It can be used to treat subacute rheumatoid arthritis, intercostal neuralgia, and ataxias.

Mechanism of Action · 4 件

The present study was aimed to test the possible cyclooxygenase (COX)-1/COX-2 selectivity of the old analgesic drug phenacetin and its metabolite p-phenetidine, which exhibits high renal toxicity. Paracetamol (acetaminophen), the main metabolite of phenacetin with low renal toxicity, and indomethacin were selected as reference compounds. Collagen-stimulated platelet thromboxane B2 (TxB2) production and phorbol 12-myristate-13-acetate (PMA)-induced neutrophil prostaglandin E2 (PGE2) synthesis were used as indicators for COX-1 and COX-2 activity, respectively. Phenacetin was even less potent than paracetamol to reduce the production of both TxB2 and PGE2, and no clear preference for either of the COX-enzymes was seen. P-phenetidine was a more potent inhibitor, already at nanomolar level, of the synthesis of these prostanoids than indomethacin and showed some preference to COX-2 inhibition. Somewhat higher, micromolar, concentrations of p-phenetidine also reduced COX-2 expression in neutrophils. We suggest that the very potent inhibitory activity of p-phenetidine on PGE2 synthesis combined with the reduction of COX-2 expression could explain the renal papillary necrosis in phenacetin kidney.

Analgesic nephropathy is a unique drug-induced kidney disease characterized pathologically by renal papillary necrosis and chronic interstitial nephritis, and is the result of excessive consumption of combination antipyretic analgesics. The clinical features of the disorder relate mainly to the papillary necrosis, renal colic, and obstructive uropathy and the development of chronic renal failure in a small percentage of patients. There are significant geographic variations in the clinical features that may be related to the differing combinations of analgesics. The pathogenesis of the disease is in part related to the kidneys' ability to concentrate drugs in the papillae. The following sequence of events presents a plausible explanation for the evolution of the disease. If a combination of phenacetin and aspirin is ingested, the following steps occur. Phenacetin is converted in the gut and liver to acetaminophen by first-pass metabolism. Acetaminophen is then taken up by the kidney and excreted. During its excretion, acetaminophen becomes concentrated in the papillae of the kidney during physiologic degrees of antidiuresis, the concentration being up to five times the intracellular concentration of other tissues. Acetaminophen undergoes oxidative metabolism by prostaglandin H synthase to a reactive quinoneimine that is conjugated to glutathione. If acetaminophen is present alone, there is sufficient glutathione generated in the papillae to detoxify the reactive intermediate. If the acetaminophen is ingested with aspirin, the aspirin is converted to salicylate and salicylate becomes highly concentrated in both the cortex and papillae of the kidney. Salicylate is a potent depletor of glutathione. The mechanism is not completely understood; however, the inhibition of the production of NADPH via the pentose shunt is a possible explanation. With the cellular glutathione depleted, the reactive metabolite of acetaminophen then produces lipid peroxides and arylation of tissue proteins, ultimately resulting in necrosis of the papillae.

関連反応

6 件
反応記録を作成
HRID 191639 の反応式
HRID 191639生成物としてTraining data from https://doi.org/10.1039/C8SC04228D (6/10)
HRID 336441 の反応式
HRID 336441生成物としてuspto-grants-2014_11
HRID 481779 の反応式
HRID 481779生成物としてuspto-grants-1998_08
HRID 1045827 の反応式
HRID 1045827生成物としてuspto-grants-2013_10
HRID 1515232 の反応式
HRID 1515232生成物としてuspto-grants-2012_07
HRID 2309933 の反応式
HRID 2309933生成物としてTraining data from https://doi.org/10.1039/C8SC04228D (10/10)

化合物ノート

読み込み中…

このページの内容基本情報概要名称と識別子物性安全と法規制化学と産業関連反応化合物ノート

データベース識別子

CAS
40674-52-0、62-44-2
PubChem CID
4754
DTXSID
DTXSID1021116
ChEMBL
CHEMBL16073
ChEBI
CHEBI:8050
UNII
ER0CTH01H9
EC Number
200-533-0、695-035-7
Nikkaji
J2.348E

In water, 766 mg/L at 25 °C

26.1 [ug/mL] (The mean of the results at pH 7.4)

Animal DrugsPharmaceuticals -> Animal Drugs -> Approved in Taiwan
Boiling Point · 3 件

Decomposes (NTP, 1992)

242-245 °C

BP: DECOMP

物理化学的性質

融点
133 · 133-136 °C (lit.)
沸点
132 °C · 132 °C / 4mmHg
比重(密度)
1.1248 · 1.1248 (rough estimate)
屈折率
1.571 · 1.5710
闪点
2 ℃ · 2℃
貯蔵温度
Sealed in dry,Room Temperature
溶解性
クロロホルム(微量)、メタノール(微量)
外見
粉
酸解離定数(Pka)
2.2 · pKa 2.2(H2O) (Uncertain);3.5(aqueous acetone) (Uncertain)
色
白い
水溶解度
0.076 g/100mL · 0.076g/100mL
Merck
14 · 14,7204
BRN
1869238 · 1869238
Henry's Law Constant
4.6 · 4.6×104 mol/(m3Pa) at 25℃, Duchowicz et al. (2020)
安定性
安定。強酸化剤、強酸とは相容れない。
化粧品成分の機能
光安定剤
InChI
1S/C10H13NO2/c1-3-13-10-6-4-9(5-7-10)11-8(2)12/h4-7H,3H2,1-2H3,(H,11,12)
InChIKey
CPJSUEIXXCENMM-UHFFFAOYSA-N
SMILES
CCOc1ccc(NC(C)=O)cc1
LogP
1.58 · 1.580
CAS データベース
62 · 62-44-2(CAS DataBase Reference)
NISTの化学物質情報
Acetamide, N-(4-ethoxyphenyl)-(62-44-2)
EPAの化学物質情報
Phenacetin (62-44-2)

化学的性質

化学的特性Acetophenetidin is a fine, white, crystalline powder or solid. Odorless with a slightly bitter taste

Hazards Summary · 1 件

The major hazards encountered in the use and handling of phenacetin stem from its toxicologic properties. Exposure to this odorless, white crystalline substance can occur from its manufacture, handling, and use as an analgesic medication, and stabilizer for hydrogen peroxide in hair bleaching preparations. Effects from exposure may include light-headedness, skin rash, methemoglobinemia, hemolytic anemia, renal papillary necrosis, convulsions, and coma. Also, the International Agency for Research on Cancer (IARC) has designated phenacetin as a Group 2A carcinogen, meaning, "The agent is probably carcinogenic to humans." Mechanical ventilation which employs a high efficiency particulate arrestor (HEPA) should be used to minimize airborne levels of phenacetin. In activities and situations where over-exposure may occur, wear a protective suit and a carefully fitted respirator. Smoking, drinking, and eating should be prohibited in phenacetin work areas, and cleanliness following the handling of phenacetin should be emphasized. Phenacetin should be stored in a securely sealed, watertight container, which should be enclosed in a second, unbreakable, leakproof container. Phenacetin is a potential candidate for rotary kiln and fluidized bed forms of incineration.

FDA Requirements · 1 件

Drug products containing certain active ingredients offered over-the-counter (OTC) for certain uses. A number of active ingredients have been present in OTC drug products for various uses, as described below. However, based on evidence currently available, there are inadequate data to establish general recognition of the safety and effectiveness of these ingredients for the specified uses: phenacetin is included in digestive aid drug products; weight control drug products; internal analgesic drug products; and orally administered menstrual drug products..

Reactive GroupAmides and Imides
Special Reports · 4 件

Bach PH, Bridges JW; Chemically Induced Renal Papillary Necrosis and Upper Urothelial Carcinoma. Part 2.; CRC Crit Rev Toxicol 15 (4): 331-441 (1985).

Clissold SP; Paracematol and Phenacetin Drugs 32 (4): 46-59 (1986)

WHO; Environmental Health Criteria 119: Principles and Methods for the Assessment of Nephrotoxicity Associated with Exposure to Chemicals (1991)

National Toxicology Program. Eleventh Report on Carcinogens (2005). The Report on Carcinogens is an informational scientific and public health document that identifies and discusses substances (including agents, mixtures, or exposure circumstances) that may pose a carcinogenic hazard to human health. Phenacetin (62-44-2) is listed as reasonably anticipated to be a human carcinogen.[Available from, as of July 31, 2009: http://ntp.niehs.nih.gov/ntp/roc/eleventh/profiles/s143phen.pdf]

RCRA Requirements · 1 件

U187; As stipulated in 40 CFR 261.33, when phenacetin, as a commercial chemical product or manufacturing chemical intermediate or an off-specification commercial chemical product or a manufacturing chemical intermediate, becomes a waste, it must be managed according to Federal and/or State hazardous waste regulations. Also defined as a hazardous waste is any residue, contaminated soil, water, or other debris resulting from the cleanup of a spill, into water or on dry land, of this waste. Generators of small quantities of this waste may qualify for partial exclusion from hazardous waste regulations (40 CFR 261.5).

Reactivity ProfilePHENACETIN react with oxidizing agents, iodine and nitrating agents. (NTP, 1992)
Air and Water ReactionsInsoluble in water.
EPA Hazardous Waste NumberU187; A toxic waste when a discarded commercial chemical product, or manufacturing chemical intermediate, or an off-specification commercial chemical product, or manufacturing chemical intermediate.

安全と保護具

Fire FightingFires involving this compound should be controlled using a dry chemical, carbon dioxide, foam or Halon extinguisher. (NTP, 1992)
First Aid · 1 件

EYES: First check the victim for contact lenses and remove if present. Flush victim's eyes with water or normal saline solution for 20 to 30 minutes while simultaneously calling a hospital or poison control center. Do not put any ointments, oils, or medication in the victim's eyes without specific instructions from a physician. IMMEDIATELY transport the victim after flushing eyes to a hospital even if no symptoms (such as redness or irritation) develop.

Fire Fighting Procedures · 1 件

Poisonous gases including nitrogen oxides are produced in fire. Use any extinguishing agent suitable for surrounding fire. If material of contaminated runoff enters waterways, notify downstream users of potentially contaminated waters. Notify local health and fire officials and pollution control agencies. If employees are expected to fight fires, they must be trained and equipped in OSHA 1910.156.

Storage Conditions · 1 件

PRECAUTIONS FOR "CARCINOGENS": Storage site should be as close as practical to lab in which carcinogens are to be used, so that only small quantities required for ... expt need to be carried. Carcinogens should be kept in only one section of cupboard, an explosion-proof refrigerator or freezer (depending on chemicophysical properties ...) that bears appropriate label. An inventory ... should be kept, showing quantity of carcinogen & date it was acquired ... Facilities for dispensing ... should be contiguous to storage area. /Chemical Carcinogens/

Cleanup Methods · 1 件

PRECAUTIONS FOR "CARCINOGENS": A high-efficiency particulate arrestor (HEPA) or charcoal filters can be used to minimize amt of carcinogen in exhausted air ventilated safety cabinets, lab hoods, glove boxes or animal rooms ... Filter housing that is designed so that used filters can be transferred into plastic bag without contaminating maintenance staff is avail commercially. Filters should be placed in plastic bags immediately after removal ... The plastic bag should be sealed immediately ... The sealed bag should be labelled properly ... Waste liquids ... should be placed or collected in proper containers for disposal. The lid should be secured & the bottles properly labelled. Once filled, bottles should be placed in plastic bag, so that outer surface ... is not contaminated ... The plastic bag should also be sealed & labelled. ... Broken glassware ... should be decontaminated by solvent extraction, by chemical destruction, or in specially designed incinerators. /Chemical Carcinogens/

Nonfire Spill Response · 1 件

SMALL SPILLS AND LEAKAGE: Should a spill occur while you are handling this chemical, FIRST REMOVE ALL SOURCES OF IGNITION, then you should dampen the solid spill material with ethanol and transfer the dampened material to a suitable container. Use absorbent paper dampened with ethanol to pick up any remaining material. Seal the absorbent paper, and any of your clothes, which may be contaminated, in a vapor-tight plastic bag for eventual disposal. Solvent wash all contaminated surfaces with ethanol followed by washing with a soap and water solution. Do not reenter the contaminated area until the Safety Officer (or other responsible person) has verified that the area has been properly cleaned.

Disposal Methods · 5 件

Generators of waste (equal to or greater than 100 kg/mo) containing this contaminant, EPA hazardous waste number U187, must conform with USEPA regulations in storage, transportation, treatment and disposal of waste.

A potential candidate for rotary kiln incineration at a temperature range of 820 to 1,600 °C and residence times of seconds for liquids and gases, and hours for solids. A potential candidate for fluidized bed incineration at a temperature range of 450 to 980 °C and residence times of seconds for liquids and gases, and longer for solids.

PRECAUTIONS FOR "CARCINOGENS": There is no universal method of disposal that has been proved satisfactory for all carcinogenic compounds & specific methods of chem destruction ... published have not been tested on all kinds of carcinogen-containing waste. ... summary of avail methods & recommendations ... /given/ must be treated as guide only. /Chemical Carcinogens/

PRECAUTIONS FOR "CARCINOGENS": ... Incineration may be only feasible method for disposal of contaminated laboratory waste from biological expt. However, not all incinerators are suitable for this purpose. The most efficient type ... is probably the gas-fired type, in which a first-stage combustion with a less than stoichiometric air:fuel ratio is followed by a second stage with excess air. Some ... are designed to accept ... aqueous & organic-solvent solutions, otherwise it is necessary ... to absorb soln onto suitable combustible material, such as sawdust. Alternatively, chem destruction may be used, esp when small quantities ... are to be destroyed in laboratory. /Chemical Carcinogens/

For more Disposal Methods (Complete) data for PHENACETIN (7 total), please visit the HSDB record page.

Preventive Measures · 5 件

PRECAUTIONS FOR "CARCINOGENS": Smoking, drinking, eating, storage of food or of food & beverage containers or utensils, & the application of cosmetics should be prohibited in any laboratory. All personnel should remove gloves, if worn, after completion of procedures in which carcinogens have been used. They should ... wash ... hands, preferably using dispensers of liq detergent, & rinse ... thoroughly. Consideration should be given to appropriate methods for cleaning the skin, depending on nature of the contaminant. No standard procedure can be recommended, but the use of organic solvents should be avoided. Safety pipettes should be used for all pipetting. /Chemical Carcinogens/

PRECAUTIONS FOR "CARCINOGENS": In animal laboratory, personnel should remove their outdoor clothes & wear protective suits (preferably disposable, one-piece & close-fitting at ankles & wrists), gloves, hair covering & overshoes. ... clothing should be changed daily but ... discarded immediately if obvious contamination occurs ... /also,/ workers should shower immediately. In chemical laboratory, gloves & gowns should always be worn ... however, gloves should not be assumed to provide full protection. Carefully fitted masks or respirators may be necessary when working with particulates or gases, & disposable plastic aprons might provide addnl protection. If gowns are of distinctive color, this is a reminder that they should not be worn outside of lab. /Chemical Carcinogens/

PRECAUTIONS FOR "CARCINOGENS": ... Operations connected with synth & purification ... should be carried out under well-ventilated hood. Analytical procedures ... should be carried out with care & vapors evolved during ... procedures should be removed. ... Expert advice should be obtained before existing fume cupboards are used ... & when new fume cupboards are installed. It is desirable that there be means for decreasing the rate of air extraction, so that carcinogenic powders can be handled without ... powder being blown around the hood. Glove boxes should be kept under negative air pressure. Air changes should be adequate, so that concn of vapors of volatile carcinogens will not occur. /Chemical Carcinogens/

PRECAUTIONS FOR "CARCINOGENS": Vertical laminar-flow biological safety cabinets may be used for containment of in vitro procedures ... provided that the exhaust air flow is sufficient to provide an inward air flow at the face opening of the cabinet, & contaminated air plenums that are under positive pressure are leak-tight. Horizontal laminar-flow hoods or safety cabinets, where filtered air is blown across the working area towards the operator, should never be used ... Each cabinet or fume cupboard to be used ... should be tested before work is begun (eg, with fume bomb) & label fixed to it, giving date of test & avg air-flow measured. This test should be repeated periodically & after any structural changes. /Chemical Carcinogens/

For more Preventive Measures (Complete) data for PHENACETIN (9 total), please visit the HSDB record page.

Protective Action Criteria (PAC) · 3 件

15 [mg/m3]

54 [mg/m3]

330 [mg/m3]

Personal Protective Equipment (PPE) · 2 件

RECOMMENDED RESPIRATOR: Where the neat test chemical is weighed and diluted, wear a NIOSH-approved half face respirator equipped with a combination filter cartridge, i.e. organic vapor/acid gas/HEPA (specific for organic vapors, HCl, acid gas, SO2 and a high efficiency particulate filter). (NTP, 1992)

PRECAUTIONS FOR "CARCINOGENS": ... Dispensers of liq detergent /should be available./ ... Safety pipettes should be used for all pipetting. ... In animal laboratory, personnel should ... wear protective suits (preferably disposable, one-piece & close-fitting at ankles & wrists), gloves, hair covering & overshoes. ... In chemical laboratory, gloves & gowns should always be worn ... however, gloves should not be assumed to provide full protection. Carefully fitted masks or respirators may be necessary when working with particulates or gases, & disposable plastic aprons might provide addnl protection. ... gowns ... /should be/ of distinctive color, this is a reminder that they are not to be worn outside the laboratory. /Chemical Carcinogens/

毒性情報

Body BurdenPhenacetin was found in breast milk of nursing mothers 0.5 to 24 hours after ingestion of an analgesic containing this compound(1).
Interactions · 5 件

Sodium 3-hydroxy-4-iodo-2-naphthoate and sodium 1-hydroxy-4-bromo-naphthoate inhibited phenacetin absorption in the rat intestine. The blood, brain and kidney levels of phenacetin decreased and the liver level increased in rats following simultaneous oral administration of phenacetin and either one. The blood levels of phenacetin in rabbits were decreased by both but were increased by sodium 1-hydroxy-2-naphthoate, sodium tetrahydro-1-hydroxy-2-naphthoate, and sodium tetrahydro-3-hydroxy-2-naphthoate. All derivatives tested decreased the in vitro metabolism of phenacetin by rat or rabbit liver slices.

The transformation of acetophenetidin to n-acetyl-p-aminophenol was increased in the liver from rats treated with caffeine or antipyrine. The lung and intestine were also capable of metabolizing acetophenetidin to form this metabolite, and this pathway was increased by exposure to cigarette smoke. Following a test dose of acetophenetidin to human subjects, the plasma levels of acetophenetidin were lower in people who smoke cigarettes than in nonsmokers. Thus, in addition to the liver, the lung and intestine may have important roles in the metabolism of acetophenetidin.

The principal route of metabolism and the total absorption of phenacetin in humans were not affected by combined ingestion of 324.0 mg phenacetin with aspirin (453.6 mg), caffeine citrate (64.8 mg) and codeine phosphate (16.2 mg) in pills taken 3 times at 2-hour intervals. The proportion of the phenacetin dose metabolized to 2-hydroxyphenetidine was increased from 1.9 to 3.4% when the drug was ingested with aspirin, caffeine, and codeine.

/Phenacetin/ potentiates the effect of caffeine on the central nervous system.

For more Interactions (Complete) data for PHENACETIN (6 total), please visit the HSDB record page.

Environmental Fate · 3 件

TERRESTRIAL FATE: Based on a classification scheme(1), an estimated Koc value of 170(SRC), determined from a log Kow of 1.58(2) and a regression-derived equation(3), indicates that phenacetin is expected to have moderate mobility in soil(SRC). Volatilization of phenacetin from moist soil surfaces is not expected to be an important fate process(SRC) given an estimated Henry's Law constant of 2.1X10-10 atm-cu m/mole(SRC), derived from its vapor pressure, 6.92X10-7 mm Hg(3), and water solubility, 766 mg/L(4). Phenacetin is not expected to volatilize from dry soil surfaces(SRC) based upon its vapor pressure(3). A theoretical BOD of 8.4% in activated sludge and using the Japanese MITI test(5), suggests that biodegradation is not a fast environmental fate process in soil(SRC).

AQUATIC FATE: Based on a classification scheme(1), an estimated Koc value of 170(SRC), determined from a log Kow of 1.58(2) and a regression-derived equation(3), indicates that phenacetin is not expected to adsorb to suspended solids and sediment(SRC). Volatilization from water surfaces is not expected(3) based upon an estimated Henry's Law constant of 2.1X10-10 atm-cu m/mole(SRC), derived from its vapor pressure, 6.92X10-7 mm(Hg(5), and water solubility, 766 mg/L(6). According to a classification scheme (7), a BCF of <30(8), suggests the potential for bioconcentration in aquatic organisms is low(SRC). A theoretical BOD of 8.4% in activated sludge and using the Japanese MITI test(8), suggests that biodegradation is not a fast environmental fate process in water(SRC).

ATMOSPHERIC FATE: According to a model of gas/particle partitioning of semivolatile organic compounds in the atmosphere(1), phenacetin, which has a vapor pressure of 6.92X10-7 mm Hg at 25 deg(2), will exist in both the vapor and particulate phases in the ambient atmosphere. Vapor-phase phenacetin is degraded in the atmosphere by reaction with photochemically-produced hydroxyl radicals(SRC); the half-life for this reaction in air is estimated to be 22 hrs(SRC), calculated from its rate constant of 1.75X10-11 cu cm/molecule-sec at 25 °C(SRC) that was derived using a structure estimation method(3). Particulate-phase phenacetin may be removed from the air by wet or dry deposition(SRC). Phenacetin does not absorb at wavelengths >290 nm(4) and therefore is not expected to be susceptible to direct photolysis by sunlight(SRC).

Milk Concentrations · 3 件

EXPERIMENTAL: Phenacetin was found in breast milk of nursing mothers 0.5 to 24 hours after ingestion of an analgesic containing this compound(1).

Phenacetin is excreted into breast milk, appearing along with its major metabolite, acetaminophen.

Phenacetin enters /breast/ milk in small quantities. /From table/

Toxicity Summary · 1 件

Phenacetin's analgesic effects are due to its actions on the sensory tracts of the spinal cord. In addition, phenacetin has a depressant action on the heart, where it acts as a negative inotrope. It is an antipyretic, acting on the brain to decrease the temperature set point. It is also used to treat rheumatoid arthritis (subacute type) and intercostal neuralgia.

Effluent Concentrations · 1 件

Phenacetin was identified in leachate from a sanitary landfill in Barcelona, Spain(1). The compound has also been identified, not quantified (detection limit of 1.0 ug/L) in tire leachates following an experiment whereby tire plugs 10.25 cm in diameter where soaked in 16 L of Lake Mead, Nevada water for a period of 31 days(2).

Medical Surveillance · 1 件

PRECAUTIONS FOR "CARCINOGENS": Whenever medical surveillance is indicated, in particular when exposure to a carcinogen has occurred, ad hoc decisions should be taken concerning ... /cytogenetic and/or other/ tests that might become useful or mandatory. /Chemical Carcinogens/

Soil Adsorption/Mobility · 1 件

The Koc of phenacetin is estimated as 170(SRC), using a log Kow of 1.58(1) and a regression-derived equation(2). According to a classification scheme(3), this estimated Koc value suggests that phenacetin is expected to have moderate mobility in soil.

Natural Pollution SourcesPhenacetin is not known to occur in nature(1).
Human Toxicity Excerpts · 5 件

/HUMAN EXPOSURE STUDIES/ Group of 623 women known regularly to ingest phenacetin-containing analgesics were compared over 4-yr period with group of 621 controls. High intake of phenacetin analgesics was assoc with increased serum creatinine levels & low urine specific gravity ... . /Phenacetin analgesics/

/HUMAN EXPOSURE STUDIES/ Chronic ingestion of large doses of analgesics (e.g., 1 kg or more of phenacetin [no longer commercially available in the US] and/or salicylate over any period of time) has been associated with analgesic nephropathy which is characterized by papillary necrosis and subsequent chronic interstitial nephritis, with or without pyelonephritis. Analgesic nephropathy frequently has been associated with ingestion of large amounts of combinations of aspirin, phenacetin, and caffeine (combinations containing phenacetin no longer are commercially available in the US). Because phenacetin previously was a component of many analgesic drug mixtures, this drug has been implicated as the causative agent of renal damage. Many clinicians, however, believe that nephropathy may be caused by a combination of several analgesics rather than a single drug. Cancer of the renal pelvis has been reported in patients with analgesic nephropathy and in patients following chronic ingestion of phenacetin-containing analgesic mixtures. Splenomegaly has also been associated with abuse of phenacetin-containing mixtures.

/SIGNS AND SYMPTOMS/ Renal tubular necrosis ... may ... occur. Phenacetin may cause methemoglobinemia & hemolytic anemia as form of acute toxicity, but more commonly as a consequence of chronic overdosage. Lethal doses of phenacetin are ... associated ... with cyanosis, respiratory depression, and cardiac arrest.

/SIGNS AND SYMPTOMS/ The /hemolytic/ anemia /assoc with chronic ingestion/ is usually mild, with slight reticulocytosis, but may be progressive & severe in presence of uremia or other exacerbating factors. Splenomegaly has been reported. Methemoglobinemia, sulfhemoglobin formation, & heinz bodies are not consistently present ... .

For more Human Toxicity Excerpts (Complete) data for PHENACETIN (25 total), please visit the HSDB record page.

Artificial Pollution SourcesPhenacetin's former production and use in the US as an analgesic(1) may have resulted in its release to the environment through various waste streams(SRC).
Environmental BiodegradationAEROBIC: Phenacetin, present at 30 mg/L, reached 8.4% of its theoretical BOD in two weeks using an activated sludge inoculum at 100 mg/L and the Japanese MITI test(1).

法規制情報

FDA Requirements · 1 件

Drug products containing certain active ingredients offered over-the-counter (OTC) for certain uses. A number of active ingredients have been present in OTC drug products for various uses, as described below. However, based on evidence currently available, there are inadequate data to establish general recognition of the safety and effectiveness of these ingredients for the specified uses: phenacetin is included in digestive aid drug products; weight control drug products; internal analgesic drug products; and orally administered menstrual drug products..

RCRA Requirements · 1 件

U187; As stipulated in 40 CFR 261.33, when phenacetin, as a commercial chemical product or manufacturing chemical intermediate or an off-specification commercial chemical product or a manufacturing chemical intermediate, becomes a waste, it must be managed according to Federal and/or State hazardous waste regulations. Also defined as a hazardous waste is any residue, contaminated soil, water, or other debris resulting from the cleanup of a spill, into water or on dry land, of this waste. Generators of small quantities of this waste may qualify for partial exclusion from hazardous waste regulations (40 CFR 261.5).

CERCLA Reportable Quantities · 1 件

Persons in charge of vessels or facilities are required to notify the National Response Center (NRC) immediately, when there is a release of this designated hazardous substance, in an amount equal to or greater than its reportable quantity of 100 lb or 45.4 kg. The toll free number of the NRC is (800) 424-8802. The rule for determining when notification is required is stated in 40 CFR 302.4 (section IV. D.3.b).

安全データ

wgk
3
tsca
TSCA listed
rtecs
AM4375000
ridadr
UN 3077 9 / PGIII
毒性
LD50 orally in rats: 1.65 g/kg (Boyd)
hs_code
29251995
risk_code
45-22-20/21/22-36-11
化審法
(3)-697
hazard_code
T,F
safety_code
53-45-36/37-26-16
Hazard Classifications
Acute Tox. 4 OralCarc. 1B
ストレージクラス
6.1C - Combustible acute toxic Cat.3toxic compounds or compounds which causing chronic effects
有毒物質データの
62-44-2(Hazardous Substances Data)

The mechanism of analgesic action has not been fully determined. Acetaminophen may act predominantly by inhibiting prostaglandin synthesis in the central nervous system (CNS) and, to a lesser extent, through peripheral action by blocking pain impulse generation. The peripheral action may also be due to inhibition of of the synthesis or actions of other substances that sensitive pain receptors to mechanical or chemical stimulation. /Acetaminophen/

Acetaminophen probably produces antipyresis by acting centrally on the hypothalamic heat-regulating center to produce peripheral vasodilation resulting in increased blood flow through the skin, sweating, and heat loss. The central action probably involves inhibition of prostaglandin synthesis in the hypothalamus. /Acetaminophen/

Biological Half-LifeThe elimination half-life (t1/2)beta varied from 37 to 74 minutes.
Metabolism/Metabolites · 6 件

Metabolised in the body to paracetamol.

Acetaminophen & phenacetin are metabolized primarily by hepatic microsomal enzymes. ... In normal individual, 75 to 80% of administered phenacetin is rapidly metabolized to acetaminophen.

... Phenacetin is converted to at least a dozen other metabolites, by n-deacetylation to para-phenetidin & by hydroxylation & further metabolism of phenacetin & para-phenetidin. An unknown metabolite, but an oxidizing agent, is responsible for methemoglobin formation & hemolysis of red blood cells ... .

Phenacetin is metabolized ... to p-acetamidophenol, which is excreted as glucuronide and sulfate conjugate ... .

... N-hydroxyphenacetin has been identified as metabolite in ... man.

For more Metabolism/Metabolites (Complete) data for PHENACETIN (15 total), please visit the HSDB record page.

MeSH Pharmacological ClassificationA subclass of analgesic agents that typically do not bind to OPIOID RECEPTORS and are not addictive. Many non-narcotic analgesics are offered as NONPRESCRIPTION DRUGS.
Absorption, Distribution and Excretion · 5 件

... Oral absorption of phenacetin is markedly influenced by particle size in the preparation, & plasma concentration of phenacetin & acetaminophen are correspondingly variable.

Peak concentration of phenacetin in plasma usually occurs in about 1 hr, & that of acetaminophen derived there from in 1-2 hr.

Absorption following oral administration is rapid ... duration of effect is about 4 hr.

Up to 45% of (14)C was recovered in 16 hr urine & 1% in feces of rats given [acetyl-(14)C]phenacetin per oral.

For more Absorption, Distribution and Excretion (Complete) data for PHENACETIN (9 total), please visit the HSDB record page.

用途と製造

Uses · 6 件

THERAP CAT: Analgesic, antipyretic /Former, US/

THERAP CAT (VET): Analgesic, antipyretic /Former, US/

As stabilizer for hydrogen peroxide in hair bleaching prepn. /Former, US/

MEDICATION (VET)

MEDICATION

Used principally as an analgesic.

Impurities... Phenacetin is available in the US as a USP grade containing 98-101% active ingredient on a dried basis and a maximum of 0.03% para-chloracetanilide. In the European Pharmacopoeia ... specifications, sulphated ash is limited to 0.1%.
U.S. Imports · 3 件

(1976) 2.32X10+8 GRAMS

(1978) 2.82X10+8 GRAMS (PRINCPL CUSTMS DISTS)

(1984) 3.75X10+7 g

U.S. Production · 3 件

2022: 28,660 lb

(1976) PROBABLY GREATER THAN 4.54X10+5 GRAMS.

(1978) PROBABLY GREATER THAN 9.08X10+5 GRAMS

Industry UsesNot Known or Reasonably Ascertainable
Methods of Manufacturing · 4 件

Condensation of p-nitrophenol in a sodium hydroxide solution with ethyl bromide followed by reduction with sodium sulfide and acetylation with acetic anhydride.

Obtained by reacting p-nitrophenol with sodium hydroxide & ethyl sulfate, reducing nitrite to amine with iron & acid, & then acetylating by boiling with glacial acetic acid.

By interaction of para-phenetidin & glacial acetic acid, or of ethyl bromide & para-acetaminophenol. Method of purification: crystallization.

Preparation: ... Eaker, Campbell, US 2887513 (1959 to Monsanto).

Formulations/Preparations · 5 件

Grades: Technical; USP, as phenacetin.

Apcabuff contains 2.5 g phenacetin per tablet.

Pharmex Flu capsules contain 2.5 g phenacetin per tablet.

Phencaset contains 150 mg phenacetin per tablet.

For more Formulations/Preparations (Complete) data for PHENACETIN (6 total), please visit the HSDB record page.

Household ProductsCosmetics product ingredient: Phenacetin
Use Classification · 2 件

Pharmaceuticals -> Animal Drugs -> Approved in Taiwan

Cosmetics -> Stabilizing

General Manufacturing Information · 6 件

All Other Basic Organic Chemical Manufacturing

Acetamide, N-(4-ethoxyphenyl)-: ACTIVE

Gives pasty mass with phenol, chloral hydrate or pyrocatechol, strong acids or alkalies, salicylic acid, oxidizers, iodine, spirit nitrous ether.

... Use of phenacetin by itself has been restricted to prescription in some countries.

Phenacetin has been employed only in analgesic mixtures. In recent years, it has been removed from almost all such mixtures. In some instances acetaminophen has been included to replace it.

A non-prostaglandin synthase inhibitor. It was utilized extensively in a wide variety of analgesic mixtures, but its causal role in analgesic-abuse nephropathy led to its withdrawal from the market. (From Smith and Reynard, Textbook of Pharmacology,1991, p431)

応用分野 · 9 件

解説フェナセチン,p-ニトロフェノールのNa塩をヨウ化エチルを用いてエチルエーテルとする.ついでニトロ基を還元しアミンとしてからアセチル化すると得られる.白色の結晶または結晶性の粉末.融点134~136 ℃.エタノール,クロロホルムに可溶,エーテル,水に難溶.下熱,鎮痛剤として用いられる.チアノーゼ,呼吸困難,頻脈,冷汗,体温降下などを伴う虚脱症状など,アセトアニリドと同様な副作用を起こす.LD50 1.65 g/kg(ラット,経口).

用途医薬(解熱剤,鎮痛剤)

用途薬理研究用、有機合成原料。

用途アニリン系化合物です。体内 でアセトアミノフェンに代謝されて作用を示 します。

用途アニリン系化合物です。体内 でアセトアミノフェンに代謝されて作用を示 します。

用途アスピリンと同様に視床下部の体温調節中枢に作用して熱放散を促進させ解熱する。アスピリンまたはアミノピリンとカフェインとによる配合剤が風邪薬として頻(ひん)用されていたが,血液障害,腎毒性,発癌作用の疑いのためほとんど使われなくなっている。

説明Phenacetin, a painkiller, was the world’s first synthetic pharmaceutical drug. It was one of the first painkillers that was not derived from opium while at the same time being absent of antiinflammatory qualities. Phenacetinwas developed in 1878 by an American chemist, Harmon Northrop Morse. It was introduced into the pharmaceutical market in 1887. However, it was withdrawn in 1983 in the United States due to unacceptable levels of interstitial nephritis in patients and potential risks of tumorigenicity. Like in the United States, most Western countries did not ban phenacetin from marketing until 1983. Phenacetin is a component of APC (aspirin-phenacetin-caffeine).

使用Analgesic, antipyretic. Component of APC tablets, analgesic mixture also containing aspirin and caffeine. Phenacetin is reasonably anticipated to be a human carcinogen; analgesic mixtures containing Phenacetin are listed as known human carcinogens.

一般的な説明Phenacetin is an odorless fine white crystalline solid with a lightly bitter taste. Used as an analgesic medicine.

調製方法 · 1 件

純化方法Crystallise it from H2O or EtOH, and its solubility in H2O is 0.08% (at ~10o) and 1.2% (at ~100o), and in EtOH it is 6.7% (at ~10o) and 36% (at ~100o). Alternatively it can be purified by solution in cold dilute alkali and re-precipitating by addition of acid to neutralisation point. Dry it in air. [Beilstein 13 H 461, 13 IV 1092.]

上流・下流製品情報

上流原料

フェネチジン4'-ヒドロキシアセトアニリド無水酢酸phenylacetic anhydride酢酸ヨウ化エチルハイドロサルファイトナトリウム

下流製品

N-アセチル-N-メチル-4-エトキシアニリン3,4-ジメトキシフェノールPhenacetin-d3Pyrrolo[2,3-b]indole, 5-ethoxy-1,2,3,3a,8,8a-hexahydro-1,3a,8-trimethyl-, (3aR,8aS)-rel-Benzothiazole, 6-ethoxy-2-methyl- (7CI,8CI,9CI)

サプライヤー100 社

国药集团化学试剂有限公司86-21-63210123 · [email protected]
北京华美互利生物化工010-56205725 · [email protected]
梯希爱(上海)化成工业发展有限公司021-67121386 · [email protected]
上海阿拉丁生化科技股份有限公司400-6206333 13167063860 · [email protected]
天津茂田科技有限公司19102267946 · [email protected]
湖北恒硕化工有限公司027-82830253 13995541600 · [email protected]
LGM Pharma1-(800)-881-8210 · [email protected]
Syntechem Co.,Ltd[email protected]
上海迈瑞尔生化科技有限公司4006356688 18621169109 · [email protected]
大连美仑生物技术有限公司0411-62910999 13889544652 · [email protected]
阿法埃莎(中国)化学有限公司400-6106006 · [email protected]
安耐吉化学&3A(安徽泽升科技股份有限公司)400-0056266 · [email protected]
北京绿百草科技发展有限公司010-61136123 · [email protected]
上海瀚鸿科技股份有限公司021-54306202 13764082696 · [email protected]
天津万象恒远科技有限公司15722085254 · [email protected]
上海隆盛化工有限公司58099637 13585536065 · [email protected]
合肥天健化工有限公司551-65418679 15856988503;15837135945 · [email protected]
BOC Sciences1-631-485-4226; 16314854226 · [email protected]
孝感深远化工有限公司15527621225; 15527621225 · [email protected]
山东西亚化学有限公司13355009207 13355009207 · [email protected]
四川库利南科技有限公司400-1166-196 18981987031 · [email protected]
天津希恩思生化科技有限公司400 638 7771 · [email protected]
湖南汇百侍生物科技有限公司0731-85526065 13308475853 · [email protected]
斯百全化学(上海)有限公司021-021-021-67601398-809-809-809 15221380277 · [email protected]
上海源叶生物科技有限公司18916372613 · [email protected]
艾科试剂4008-755-333 18080918076 · [email protected]
上海思域化工科技有限公司86-21-34053660 · [email protected]
赛默飞世尔科技(中国)有限公司800-810-5118 · [email protected]
北京伊诺凯科技有限公司400-810-7969 010-59572699 · [email protected]
AdooQ BioScience, LLC+1 (866) 930-6790 · [email protected]
TCI AMERICA800-4238616 · [email protected]
TOKYO CHEMICAL INDUSTRY CO., LTD.03-36680489 · [email protected]
上海贤鼎生物科技有限公司4009209199 · [email protected]
深圳振强药物研发有限公司0755-66853366 13670046396 · [email protected]
Hubei Datong Bio-Chemical Technology Co.,Ltd027-87666700 · [email protected]
深圳市石金谷科技有限公司(0086)755-61930359 (0086)18038192047 · [email protected]
北京环宇世纪化学科技有限公司hysj_bj.com
湖北鑫源顺医药化工有限公司13971561712, 13995564702, 027-50664929 · [email protected]
上海将来实业股份有限公司400-0066400 13621662912 · [email protected]
上海将来实业股份有限公司021-61552785 · [email protected]
安徽科迪达化工有限公司0554-2106669 · [email protected]
四川省维克奇生物科技有限公司028-81700200 18116577057 · [email protected]
成都零六生物科技有限公司400-1166-196 13458535857 · [email protected]
上海御略医药科技有限公司021-60345187 13671753212 · [email protected]
上海麦克林生化科技股份有限公司15221275939 15221275939 · [email protected]
杭州杰恒化工有限公司0571-87396432 · [email protected]
上海永叶生物科技有限公司86-021-61559134 15921386130 · [email protected]
江苏艾康生物医药研发有限公司025-66028182 17714375163 · [email protected]
南京百鑫德诺生物科技有限公司025-58849295 · [email protected]
凯试(上海)科技有限公司021-50135380 · [email protected]
補足説明 · 1 件

定義ChEBI: Phenacetin is a member of the class of acetamides that is acetamide in which one of the hydrogens attached to the nitrogen is substituted by a 4-ethoxyphenyl group. It has a role as a non-narcotic analgesic, a peripheral nervous system drug and a cyclooxygenase 3 inhibitor. It is a member of acetamides and an aromatic ether. It is functionally related to a N-phenylacetamide, a 4-ethoxyaniline and a paracetamol.